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1  | INTRODUC TION
Adrenocorticotropin (ACTH)- dependent hypercortisolism, or 
Cushing’s syndrome, is most commonly caused by a corticotropin- 
secreting pituitary adenoma (Cushing’s disease). Ectopic ACTH 
syndrome (EAS) occurs in a small fraction of patients with endog-
enous hypercortisolemia, due to extra- pituitary sources of corti-
cotropin or, rarely, CRH.1,2 EAS is associated with various benign and 
 malignant tumours, most commonly bronchial/pulmonary, thymic 
or pancreatic neuroendocrine tumours (NET) and, rarely, small cell 
lung carcinoma (SCLC), pheochromocytoma and medullary thyroid 
carcinoma (MTC). Cushing’s syndrome is associated with cardiovas-
cular, metabolic, infectious and skeletal complications, regardless of 
aetiology.3-7 In particular, EAS can be fulminant, leading to altered 
mental status, thromboembolism and/or opportunistic infections.3 
The first- line treatment for all forms of clinically overt Cushing’s 
syndrome is surgical removal of the hormonally active tumour. Not 
uncommonly, however, EAS originates in occult tumours, which are 
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Summary
Objectives: Mifepristone, a glucocorticoid receptor antagonist, can be used to man-
age hypercortisolism in patients with ectopic adrenocorticotropic hormone syn-
drome (EAS) when surgical cure is not feasible. Outcomes of EAS patients treated 
with mifepristone have been limited to reports of isolated cases. We aimed to deter-
mine the efficacy and limitations of mifepristone in the treatment of EAS and to 
compare outcomes with those of patients who underwent bilateral adrenalectomy.
Method: A retrospective cohort study of EAS patients from the University of 
Michigan between 1997 and 2017 was conducted.
Results: Of the 55 patients with EAS, 16 were treated with mifepristone: eight neu-
roendocrine tumours, two carcinomas and six occult tumours. Treatment with mife-
pristone was most commonly prompted by psychosis, uncontrolled glucose and/or 
hypertension. The median maintenance dose was 600 mg/d. Amelioration of psycho-
sis was observed within 48 hours in 3/3 patients, and the glycaemic control was im-
proved in 14/16 patients. The median duration of treatment was 9 months, and three 
patients were treated for more than 24 months. The overall survival at 24 months 
was equivalent between patients with EAS treated with mifepristone vs bilateral 
 adrenalectomy (N = 12) (P = 0.6).
Conclusions: Mifepristone is effective in treating EAS for over 2 years, and survival 
was not different from that of patients treated with bilateral adrenalectomy. 
Aggressive concomitant therapy for hypokalaemia and hypertension is necessary.
K E Y W O R D S
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difficult to localize despite extensive imaging.8-13 Furthermore, sur-
gical cure is achieved in less than half of EAS patients,9,10 with per-
sistent hypercortisolism.
Medical therapy can be used preoperatively in patients who re-
quire immediate control of hypercortisolism, in poor surgical can-
didates or when the source of Cushing’s syndrome is occult.14,15 
Bilateral adrenalectomy is typically reserved for patients with sur-
gically incurable Cushing’s syndrome and difficult to control hy-
percortisolism.16-18 Nevertheless, bilateral adrenalectomy leads to 
permanent adrenal insufficiency and creates the need for lifelong 
glucocorticoid and mineralocorticoid replacement, with the risk of 
fatal adrenal crises.17,18
Mifepristone, a glucocorticoid receptor antagonist, was approved 
by US Food and Drug Administration in 2012 for the management of 
hypercortisolism- induced hyperglycaemia in patients with endoge-
nous Cushing’s syndrome who have failed or are not candidates for 
surgical cure.19 Circulating ACTH and cortisol concentrations can-
not serve as indicators for disease control and commonly increase in 
some forms of Cushing’s syndrome during treatment with mifepri-
stone.20,21 A prospective, multicentre trial conducted to assess the 
efficacy and safety of mifepristone in endogenous Cushing’s syn-
drome focused mainly on patients with Cushing’s disease (86%) and 
showed robust improvement in clinical and metabolic parameters.22 
Outcomes of patients with EAS treated with mifepristone, however, 
have been only reported in isolated cases and for short intervals of 
time.23-26 Because EAS is often more aggressive clinically and also 
more difficult to cure due to occult or metastatic sources of ACTH, 
we aimed to assess the efficacy and safety of mifepristone in the 
treatment of EAS.
2  | MATERIAL S AND METHODS
We conducted a cohort study of all patients with EAS evaluated at 
the University of Michigan between January 1997 and December 
2017. Patients’ demographics, clinical presentation, imaging, labora-
tory, and pathological and treatment data were retrospectively re-
viewed. The study was conducted with the University of Michigan 
Institutional Review Board approval (HUM0091004). A waiver of 
consent was granted for this retrospective study.
The diagnosis and source of Cushing’s syndrome were based 
on the clinical and hormonal evaluation, in accordance with the 
Endocrine Society guidelines.4 Occult primary tumours were de-
fined as unidentified sources of Cushing’s syndrome despite com-
prehensive investigations by cross- sectional imaging [computed 
tomography (CT) and magnetic resonance imaging (MRI)] and func-
tional imaging [octreotide scan, [18F]- fluorodeoxyglucose positron 
emission tomography (FDG- PET) and [68Ga]- DOTATATE PET/CT]. 
The efficacy of mifepristone was assessed based on the amelioration 
of psychotic symptoms, glucose and hypertension.
Statistical differences in measured parameters between 
groups were evaluated using the Mann- Whitney U- test. The 
Kaplan- Meier analysis was applied to evaluate the median overall 
survival between patients with EAS treated with mifepristone vs 
bilateral adrenalectomy. A value of P < 0.05 was considered statis-
tically significant.
3  | RESULTS
From January 1997 to December 2017, 55 patients with EAS were 
evaluated in our institution. Of these, five patients, who were re-
ferred to our center for inferior petrosal sinus sampling and lacked 
treatment and follow- up data, were excluded. Of the remaining 
50 patients, 16 were treated with mifepristone, whereas 34 pa-
tients received other therapies (12 bilateral adrenalectomy, 11 
primary tumour resections, five other medical treatment and six 
combined medical modalities) (Figure 1). Mifepristone was used as 
the initial medical agent in eight patients; the remaining eight pa-
tients were previously treated with ketoconazole (8), metyrapone 
F IGURE  1 Patients with ectopic 
adrenocorticotropic hormone syndrome 
(EAS) evaluated at the University of 
Michigan (1997- 2017) and treatment 
modalities
Other modalities to manage 
hypercortisolism
N = 22
Ectopic ACTH tumour resection N = 11
Medical treatment only                N = 5
Combined treatment                    N = 6
EAS
N = 55
1997-2017
Bilateral adrenalectomy
N = 2
N = 5 excluded (treatment data 
unavailable, outside referral)
Bilateral adrenalectomy
N = 12
Mifepristone
N = 16
No mifepristone
N = 34
N = 50
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(1) and/or octreotide (2). Of the patients treated with mifepristone, 
two patients eventually underwent bilateral adrenalectomy, 8 and 
28 months after the initiation of mifepristone, respectively, due to 
the poor control of hypertension and hypokalaemia.
The median age at the time of EAS diagnosis was 49 years (range 
25- 75 years) in patients treated with mifepristone, and 13 (81%) 
patients were women. EAS was caused by: NET in eight patients 
(two medullary thyroid cancers, two bronchial, two thymic and two 
gastroenteropancreatic NET); carcinoma in two patients (one naso-
pharyngeal and one non-small cell lung cancer); and occult primary 
tumour in six patients. Metastases were present at the time of the 
initial evaluation in eight (50%) patients. Baseline urinary free corti-
sol and plasma ACTH concentrations were similar between patients 
treated with mifepristone and bilateral adrenalectomy  (Table 1).
The baseline clinical characteristics of the 16 patients with EAS 
treated with mifepristone are presented in Table 2. The most com-
mon metastatic sites were lymph nodes, liver and lung. Mifepristone 
was used in three patients with severe Cushing’s syndrome prior to 
surgical resection of the primary tumour; in 13 patients, curative sur-
gery was not feasible (metastatic disease in seven patients and oc-
cult EAS in six patients). With one exception, all patients had clinical 
signs of Cushing’s syndrome: facial fullness, plethora, purplish striae, 
easy bruising, proximal muscle weakness, central obesity, dorsocer-
vical hump and/or supraclavicular fullness. Neurocognitive symp-
toms were noted in 6/16 (38%) of patients and varied from memory 
impairment to depression and acute psychosis. Abnormal glycaemic 
status was present in all patients (nine poorly controlled diabetes 
mellitus and seven patients with new onset hyperglycaemia), and 
insulin therapy was initiated in three patients. All patients had hy-
pertension and hypokalaemia prior to the initiation of mifepristone.
Mifepristone was initiated at the dose of 300 mg/day in all pa-
tients and subsequently increased every 2- 4 weeks based on the 
clinical response and side effects’ assessment. The median main-
tenance dose used without adverse events was 600 mg/day (range 
300- 1200 mg). The median duration of mifepristone treatment was 
9 months (range 0.25- 28 months, Table 3). Mifepristone was with-
held in two patients due to hypotension and hypoglycaemia, and 
treatment with dexamethasone was promptly initiated (patients 5 
and 14, Table 3). In one patient treated with 600 mg/d for 2 months, 
mifepristone therapy was interrupted during a urinary tract infec-
tion, reinitiated after resolution and subsequently titrated up to 
1200 mg without further side effects. The other patient developed 
a haemothorax and respiratory failure following thoracentesis for 
a recurrent pleural effusion. She required sedation and intubation, 
and mifepristone therapy was therefore changed to intravenous 
etomidate.
Following the treatment with mifepristone, two patients sub-
sequently underwent bilateral adrenalectomy. After 28 months 
of mifepristone therapy, patient number 14 suffered a seizure of 
unknown aetiology with acute kidney injury, poorly controlled hy-
pertension and serum potassium fluctuations. The source of ACTH 
remained occult, and at that time, replacement therapy for adrenal 
insufficiency was deemed safer than medical management of hy-
percortisolism for her chronic care. Patient number one had widely 
metastatic medullary thyroid cancer, which initially responded to 
cabozantinib, but her tumour burden and hypercortisolism later 
progressed. She developed proximal muscle weakness, pedal 
oedema and severe hypertension during treatment with mifepri-
stone 1200 mg/d plus spironolactone, amiloride and potassium 
supplements. Because her reliance on multiple drugs for hyper-
cortisolism would compromise potential oncologic therapies, her 
adrenals were removed. Both patients improved clinically with 
glucocorticoid replacement following bilateral adrenalectomy, al-
though patient number one later died due to progression of her 
cancer metastases.
In all three patients with acute psychosis, the symptoms im-
proved within 48 hours after initiating mifepristone. Amelioration of 
depressive symptoms and memory impairment occurred over a few 
weeks in 3/3 patients. Glycaemic control was improved in 14/16 pa-
tients: five with newly diagnosed hyperglycaemia and nine with un-
controlled diabetes, three of whom stopped all antidiabetic agents. 
While on mifepristone treatment, four patients had improved blood 
pressure control; seven patients required intensification of the an-
tihypertensive regimen, particularly by adding a mineralocorticoid 
receptor antagonist; and five patients had worsening hypertension 
despite more aggressive treatment (Table 3).
Minor side effects of mifepristone were reported during 
treatment, most commonly fatigue (50%), anorexia (31%), nausea 
TABLE  1 Patient characteristics
All patients  
N = 50
Patients treated  
with mifepristone  
N = 16
Patients who underwent 
bilateral adrenalectomy  
N = 12
P value (mifepristone vs bilateral 
adrenalectomy)
Sex (M/F) 18/32 3/13 5/7 0.14
Age (range), y 48 (11- 75) 49 (25- 75) 38 (11- 64) 0.14
Solitary/metastatic 20/30 8/8 3/9 0.13
Occult source 10 6 2
ACTH (pg/mL) 173 [111- 310] 169 [113- 310] 209 [133- 508] 0.45
24 h- UFC (μg/24 h) 1229 [633- 3469] 1000 [423- 3935] 1613 [671- 3650] 0.50
Data are expressed as medians [interquartile range]. To convert ACTH to pmol/L, multiply by 0.222. To convert UFC to nmol/24 h, multiply by 2.76.
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and vomiting (31%), and oedema (19%) (Table 4). Worsening hy-
pokalaemia and increased blood pressure were observed in 31% 
of mifepristone- treated patients, but only one patient experi-
enced severe hypokalaemia (serum potassium level ≤2.5 mmol/L). 
Hypokalaemia was more common in patients receiving >600 mg/d 
of mifepristone. The antihypertensive medications, especially 
mineralocorticoid receptor antagonist, and oral potassium re-
placement were adjusted during mifepristone treatment. Patients 
were treated with up to 300 mg of spironolactone or eplere-
none, 20 mg of amiloride and 200 mEq/d of potassium. The me-
dian maintenance dose of spironolactone was 200 mg/d (range 
50- 300 mg/d). Mifepristone dose reduction was required in two 
patients due to symptoms of glucocorticoid withdrawal, such as 
persistent anorexia.
During the follow- up period, 11 patients died: five patients 
treated with mifepristone and six patients who underwent bilat-
eral adrenalectomy. Of the five patients treated with mifepristone, 
four had widely metastatic malignancies (bronchial, thymic, naso-
pharyngeal and medullary thyroid carcinoma) and one patient with 
metastatic thymic carcinoma died from acute respiratory failure. 
Of the six patients who had undergone bilateral adrenalectomy, all 
died with widely metastatic malignancies (three gastrinoma, one 
medullary thyroid carcinoma, one thymic carcinoma and one pancre-
atic neuroendocrine tumour). The overall survival at 24 months was 
equivalent between patients with EAS treated with mifepristone 
vs those with bilateral adrenalectomy (58% vs 55%, respectively, 
P = 0.625 Figure 2).
4  | DISCUSSION
Herein, we present our experience with mifepristone in the treat-
ment of EAS, compared to previous experience limited to very few 
reports. EAS is often clinically fulminant, and effective medical 
therapies are important in managing hypercortisolism and its com-
plications in preparation for curative surgery. Furthermore, because 
ectopic corticotropin- secreting tumours can be occult, medical 
therapy can be continued until the source of EAS is identified, ob-
viating the need for bilateral adrenalectomy. Our data demonstrate 
the efficacy of mifepristone in resolving psychotic symptoms within 
48 hours of initiation. In addition, mifepristone improved glycaemic 
control and blood pressure in 88% and 69% of the EAS patients, re-
spectively. A previous study showed improved glycaemic control in 
60% of patients, with nearly half being able to reduce the intensity of 
TABLE  2 Characteristics of mifepristone- treated patients (before initiation)
Sex
Age 
(y) Primary tumours Distant metastasis
Psychiatric 
symptoms Glycaemic status
Previous 
medications
MRA(mg/d) and K+ 
supplements 
(mEq/d)
1 F 49 MTC LN, Liver, Bone No New- onset 
hyperglycaemia
Ketoconazole, 
octreotide
SPL 25, K 120
2 F 32 MTC LN, Lung, Liver, Bone No Uncontrolled DM None SPL 50, K 40
3 F 75 Bronchial NET None Psychosis Uncontrolled DM Ketoconazole SPL 100
4 F 66 Bronchial NET LN, Cutaneous Memory loss Uncontrolled DM Ketoconazole SPL 50, K 20
5 M 49 Pancreatic NET LN, Liver No Uncontrolled DM None SPL 200, K 160
6 F 67 Ileal NET Lung, Peritoneum, 
Ovary, Pancreas
No New- onset 
hyperglycaemia
Octreotide SPL 25, K 20
7 M 37 Thymic NET LN Psychosis Uncontrolled DM None SPL 50, K 60
8 M 25 Thymic NET LN, Brain, Bone No New- onset 
hyperglycaemia
Ketoconazole, 
metyrapone
EPL 100, K 100
9 F 47 Nasopharyngeal 
carcinoma
Lung, Bone No New- onset 
hyperglycaemia
Ketoconazole SPL 100
10 F 60 NSCLC None No New- onset 
hyperglycaemia
None SPL 25
11 F 33 Occult None Depression Uncontrolled DM Ketoconazole SPL 50
12 F 74 Occult None Psychosis Uncontrolled DM None SPL 50, AMI 5, K 80
13 F 56 Occult None No Uncontrolled DM Ketoconazole SPL 50, K20
14 F 28 Occult None No New- onset 
hyperglycaemia
None SPL 200
15 F 65 Occult None Depression New- onset 
hyperglycaemia
None SPL 50, K 20
16 F 46 Occult None No Uncontrolled DM None SPL 50
Age, age in years; AMI, amiloride; EPL, eplerenone; F, female; IFG, impaired fasting glucose; K+, potassium replacement in mEq/d; LN, lymph node; 
M, male; MRA, mineralocorticoid receptor antagonist; MTC, medullary thyroid cancer; NET, neuroendocrine tumor; NSCLC, nonsmall cell lung cancer; 
PG, plasma glucose; psychiatric symptoms, included psychosis, depression and memory loss; SPL, spironolactone.
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antidiabetic regimen.22 In our cohort, hyperglycaemia was improved 
in 14/16 patients, and in three patients, all antidiabetic agents were 
discontinued.
Hypokalaemia was present at the time of diagnosis in all EAS 
patients and remained problematic during mifepristone treatment, 
similar to what has been reported previously.10,24 The massive 
glucocorticoid excess in patients with EAS exceeds the capac-
ity of 11β- hydroxysteroid dehydrogenase type two to inactivate 
cortisol to cortisone, which thus activates the mineralocorticoid 
receptor.21,22,27,28 An accurate assessment of mifepristone’s contri-
bution to hypokalaemia in our patients with EAS was difficult, due 
to overlapping factors, such as elevation of ACTH and cortisol due 
to the progression of tumours; concomitant tubular dysfunctions 
from chemotherapy; or severe vomiting and diarrhoea. Correction 
of hypokalaemia during treatment with mifepristone required up 
to 300 mg/d of spironolactone and/or up to 240 mEq/d of potas-
sium, similar to a previous report.22 These data suggest that serum 
potassium should be aggressively treated and closely monitored in 
patients with EAS during all stages and in particular when mifepri-
stone is used.
A major consideration when using mifepristone in clinical prac-
tice is the inability to utilize serum or urine cortisol measurements 
as indicators of disease control. In addition, symptoms of gluco-
corticoid withdrawal are expected during mifepristone therapy, 
as well as continued clinical manifestations of hypercortisolism. In 
patients treated with mifepristone who experience hypotension, 
hypoglycaemia, nausea and vomiting, weakness and dizziness, 
TABLE  3 Clinical data during mifepristone treatment
Primary tumours
Maintenance 
dose (mg/d)
Duration of 
mifepristone 
treatment (mo)
Reason for 
cessation 
mifepristone
Clinical and biochemical 
improvement after treatment
MRA(mg/d) and K+ 
supplements (mEq/d)
Psychiatric 
symptoms
Glycaemic 
control HTN
1 MTC 1200 8 Bilateral 
adrenalectomy
- Yes No SPL 300, AMI 5, K 80 (^)
2 MTC 600 1 Death* - Yes Yes SPL 150, K 40 (^)
3 Bronchial NET 300 8 Cure Yes Yes* Yes SPL 100
4 Bronchial NET 300 4 Death* Yes Yes Yes SPL 200 (^)
5 Pancreatic NET 300 0.5 Etomidate - Yes* Yes SPL 300, K 90 (^)
6 Ileal NET 300 10 Cure - Yes Yes K 20 (˅)
7 Thymic NET 900 12 Cure Yes Yes* No EPL 100, K 240 (^)
8 Thymic NET 1200 16 Death* - No No EPL 300, AMI 20, K 200 
(^)
9 Nasopharyngeal 
carcinoma
900 1.5 Death* - Yes Yes SPL 250 (^)
10 NSCLC 1200 27 Ongoing - Yes No SPL 300 (^)
11 Occult 600 13 Ongoing Yes Yes Yes SPL 50
12 Occult 300 0.25 Ongoing Yes Yes Yes SPL 100, AMI 5 (^)
13 Occult 600 10 Ongoing - Yes Yes SPL 50
14 Occult 1200 28 Bilateral 
adrenalectomy
- Yes No SPL 300, K 120 (^)
15 Occult 600 7 Ongoing Yes No Yes SPL 100, K 40 (^)
16 Occult 300 28 Ongoing - Yes Yes SPL 200, K 100 (^)
−, Negative; AMI, amiloride; BA, Clinical signs, signs of cushing syndrome (plethora, purplish striae, round face, etc.); Death*, death from tumor progres-
sion; EPL, eplerenone; Etomidate, changed treatment to etomidate; K+, potassium replacement in mEq/d; MRA, mineralocorticoid receptor antagonist; 
MTC, medullary thyroid cancer; NET, neuroendocrine tumor; NSCLC, non- small cell lung cancer; Psychiatric symptoms, included psychosis, depression 
and memory loss; SPL, spironolactone; Yes*, improved glycemic control with cessation of all antidiabetic agents.
During therapy with mifepristone, changes in K supplements and MRA are indicated by (˄) for dose increase and (˅) for dose decrease.
TABLE  4 Adverse effect of mifepristone
Adverse events
Number of 
patients
Fatigue 8
Oedema 3
Nausea and vomiting 5
Anorexia 5
Glucocorticoid treatment 2
Increased dose of MRA and potassium supplementation 12
Abnormal vaginal bleeding, of 13 women 1
MRA, mineralocorticoid receptor antagonist.
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mifepristone should be discontinued, and dexamethasone should 
be initiated promptly.29 In our study, only two patients required 
interruption of mifepristone and dexamethasone treatment, and 
of these, one case had transient symptoms, precipitated by an ep-
isode of urinary tract infection. Nonetheless, a severe illness that 
demands augmented glucocorticoid activity should be promptly 
treated, and frequent clinical reassessment should be used to 
guide further therapy.
Our study substantiates the efficacy of mifepristone in the 
management of EAS, for both acute and extended management 
of hypercortisolism. Importantly, mifepristone was safely used for 
over 2 years in three of our patients. Survival for patients treated 
with mifepristone was similar to those managed with bilateral 
adrenalectomy, and tumour progression was the major cause of 
death. The small number of patients and the retrospective study 
design limit the extrapolation of our results. While the severity of 
hypercortisolemia was comparable between patients treated with 
mifepristone vs bilateral adrenalectomy, both groups were hetero-
geneous with respect to aetiology of EAS and clinical features, and 
treatment choice was not randomized. Mifepristone, along with a 
mineralocorticoid receptor antagonist and potassium supplemen-
tation, is effective in patients who cannot undergo bilateral adre-
nalectomy immediately or with occult tumours while searching for 
the source.
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